CA3199006A1 - Anti-cd25 antibodies - Google Patents

Anti-cd25 antibodies

Info

Publication number
CA3199006A1
CA3199006A1 CA3199006A CA3199006A CA3199006A1 CA 3199006 A1 CA3199006 A1 CA 3199006A1 CA 3199006 A CA3199006 A CA 3199006A CA 3199006 A CA3199006 A CA 3199006A CA 3199006 A1 CA3199006 A1 CA 3199006A1
Authority
CA
Canada
Prior art keywords
antibodies
human
relates
present
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199006A
Other languages
English (en)
French (fr)
Inventor
Daniel Olive
Armand Bensussan
Jerome Giustiniani
Anne Marie-Cardine
Arnaud Foussat
Jemila HOUACINE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alderaan Biotechnology
Aix-Marseille Université
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Université Paris-Est Créteil Val de Marne
Institute Paoli-Calmettes
Université Paris Cité
Original Assignee
Alderaan Biotechnology
Aix-Marseille Université
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
Université Paris-Est Créteil Val de Marne
Institute Paoli-Calmettes
Université Paris Cité
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alderaan Biotechnology, Aix-Marseille Université, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université Paris-Est Créteil Val de Marne, Institute Paoli-Calmettes, Université Paris Cité filed Critical Alderaan Biotechnology
Publication of CA3199006A1 publication Critical patent/CA3199006A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3199006A 2020-11-20 2021-11-19 Anti-cd25 antibodies Pending CA3199006A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306424.1 2020-11-20
EP20306424 2020-11-20
PCT/EP2021/082383 WO2022106665A1 (en) 2020-11-20 2021-11-19 Anti-cd25 antibodies

Publications (1)

Publication Number Publication Date
CA3199006A1 true CA3199006A1 (en) 2022-05-27

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199006A Pending CA3199006A1 (en) 2020-11-20 2021-11-19 Anti-cd25 antibodies

Country Status (9)

Country Link
US (1) US20240002522A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247497A1 (cg-RX-API-DMAC7.html)
JP (1) JP7886328B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118108A (cg-RX-API-DMAC7.html)
CN (1) CN116917318A (cg-RX-API-DMAC7.html)
AR (1) AR124123A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021380966A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022106665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2013165972A2 (en) * 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019008386A1 (en) * 2017-07-06 2019-01-10 Tusk Therapeutics Ltd COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR
CN112020516B (zh) * 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN114630838A (zh) * 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体

Also Published As

Publication number Publication date
JP2023550446A (ja) 2023-12-01
EP4247497A1 (en) 2023-09-27
AR124123A1 (es) 2023-02-15
CN116917318A (zh) 2023-10-20
US20240002522A1 (en) 2024-01-04
KR20230118108A (ko) 2023-08-10
AU2021380966A1 (en) 2023-06-22
JP7886328B2 (ja) 2026-07-07
WO2022106665A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2020012607A (es) Anticuerpos especificos para gucy2c y sus usos.
ZA202100721B (en) Anti-mesothelin antibodies
SA520420582B1 (ar) Cd3 أجسام مضادة خاصة لـ واستخداماتها
EP4257199A3 (en) Humanized anti-human-pd-1 antibody
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
WO2020014460A8 (en) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
WO2017220989A8 (en) ANTI-PD-L1 AND CYTOKINES IL-2
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
ZA202209119B (en) Anti-human cd19 antibodies
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
AU2014233478A8 (en) Anti-CD25 antibodies and their uses
ZA202309516B (en) Anti-ccr8 antibodies
MX2020008122A (es) Anticuerpos anti-pd-1.
PH12021552903A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CR20200623A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2018006410A (es) Proteinas de union a cd131 y usos de las mismas.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
ZA202305072B (en) Cd1a antibodies and uses thereof
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2025007213A (es) Anticuerpos dirigidos a cd45

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241127

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241127

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260430